Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.56 |
| ▸ | CA2 | P00918 | 3/20 | 0.56 |
| ▸ | CA12 | O43570 | 2/20 | 0.56 |
| ▸ | CA3 | P07451 | 2/20 | 0.56 |
| ▸ | CA5A | P35218 | 2/20 | 0.56 |
| ▸ | CA7 | P43166 | 2/20 | 0.56 |
| ▸ | CA9 | Q16790 | 2/20 | 0.56 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.56 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.56 |
| ▸ | CA4 | P22748 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.46 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.46 |
| ▸ | CDC25B | P30305 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 5/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | APEX1 | P27695 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL643634 | 0.86 | KDM4E (0.50) | CA1CA2CA12CA3CA5A | |
| SCHEMBL9902960 | 0.83 | ALDH1A1 (0.55) | CA1CA2CA12CA3CA5A | |
| SCHEMBL12433977 | 0.77 | CA12 (0.64) | CA1CA2CA12CA3CA5A | |
| SCHEMBL2644319 | 0.77 | POLB (0.40) | CA1CA2CA12CA3CA5A | |
| SCHEMBL28685071 | 0.75 | GBA1 (0.45) | CA1CA2CA12CA3CA5A | |
| SCHEMBL9097330 | 0.74 | CDC25B (0.48) | CA1CA2CA12CA3CA5A | |
| SCHEMBL8358315 | 0.74 | KDM4E (0.54) | KDM4ESMN1; SMN2KCNA3NPC1RAB9A | |
| SCHEMBL2663325 | 0.74 | KDM4E (0.41) | CA1CA2CA12CA7CA9 | |
| SCHEMBL28878363 | 0.72 | CA12 (1.00) | CA1CA2CA12CA3CA5A | |
| SCHEMBL642731 | 0.72 | ALDH1A1 (0.42) | KDM4ESMN1; SMN2KCNA3POLBNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7365077-B2 | Piperazine bis-amide derivatives and their use as antagonists of the orexin receptor | SMITHKLINE BEECHAM P.L.C. (GB) | 2008-04-29 | — | — | US | claimed |
| US-7365077-B2 | Piperazine bis-amide derivatives and their use as antagonists of the orexin receptor | SMITHKLINE BEECHAM P.L.C. (GB) | 2008-04-29 | — | — | US | disclosed |
| US-20060252769-A1 | Piperazine bis-amide derivatives and their use as antagonists of the orexin receptor | SMTIHKLINE BEECHAM P.L.C. (GB) | 2006-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252769-A1 | Piperazine bis-amide derivatives and their use as antagonists of the orexin receptor | HCRTR2, HCRTR1, NPSR1 | CA1 1450/4885CA2 1216/4885CA12 3230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.